Drug Details

General Information of the Drug (ID: DR6126)
Name
Amifostine
Synonyms
amifostine; 20537-88-6; Ethiofos; Gammaphos; Ethyol; Sapep; Apaetp; Aminopropylaminoethyl thiophosphate; WR 2721; NSC-296961; YM-08310; 2-(3-Aminopropylamino)ethyl thiophosphate; AU-95722; UNII-ILA426L95O; NSC296961; Amifostine (Hydrate); WR2721; NSC 296961; WR-2721; S-(2-(3-Aminopropylamino)ethyl) phosphorothioate; CHEBI:2636; ILA426L95O; WR 2721C; Amifostina; NCGC00015073-02; S-(2-((3-Aminopropyl)amino)ethyl) dihydrogen phosphorothioate; Ethanethiol, 2-[(3-aminopropyl)amino]-, 1-(dihydrogen phosphate); 2-((3-Aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9CI); DSSTox_CID_2585; Ethiofos Anhydrous; DSSTox_RID_76644; DSSTox_GSID_22585; C5H15N2O3PS; ({2-[(3-aminopropyl)amino]ethyl}sulfanyl)phosphonic acid; S-{2-[(3-aminopropyl)amino]ethyl} dihydrogen thiophosphate; Amifostine Ethiofos; Amifostine Anhydrous; Amifostine [USAN:INN:BAN]; CAS-20537-88-6; S-[2-(3-Aminopropylamino)ethyl] phosphorothioate; SR-01000075680; BRN 2088122; YM 08310; S-[2-[(3-Aminopropyl)amino]ethyl] dihydrogen phosphorothioate; CCRIS 9316; HSDB 7560; Amifostine,(S); 2-(3-aminopropylamino)ethylsulfanylphosphonic acid; Amifostine disulfide; S,2-(3-Aminopropylamino)ethyl-phosphorothioic acid; S-2-(3-Aminopropylamino)ethyl phosphorothioic acid; Ethyol;WR2721; Spectrum_000332; S-omega-(3-Aminopropylamino)ethyl dihydrogen phosphorothioate; SpecPlus_000647; 2-(3-Aminopropyl)aminoethylphosphorothioate; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique [French]; Spectrum5_001920; Lopac-A-5922; Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester); NCIMech_000622; S 8744; CHEMBL1006; Lopac0_000029; SCHEMBL18464; KBioSS_000812; cc-307; MLS000028473; S-2-(3-aminopropylamino)-ethylphosphorothioic acid; BIDD:GT0059; DivK1c_006743; WR-2721 TRIHYDRATE; DTXSID8022585; KBio1_001687; KBio2_000812; KBio2_003380; KBio2_005948; Acide ((amino-3 propylamino)-2 ethyl)-S-phosphorothioique; HMS2090I03; HMS3260E19; HMS3713C06; Pharmakon1600-01503081; Phosphorothioic acid, S-(2-(3-aminopropylamino)ethyl) ester; BCP08957; HY-B0639; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl] ester; Tox21_110077; Tox21_500029; CCG-35734; MFCD00233058; NSC758236; ZINC21992285; AKOS015895196; Tox21_110077_1; AC-1126; DB01143; LP00029; NSC-758236; SDCCGSBI-0050018.P005; SMP2_000335; NCGC00015073-01; NCGC00015073-03; NCGC00015073-04; NCGC00015073-05; NCGC00015073-15; NCGC00093549-01; NCGC00093549-02; NCGC00260714-01; AS-13020; Ethanethiol, dihydrogen phosphate (ester); NCI60_002485; SMR000058413; Ethanethiol, dihydrogen phosphate- (ester); SBI-0050018.P003; AB0012846; EU-0100029; FT-0622272; 37A886; A 5922; C06819; [2-(3-aminopropylamino)ethylthio]phosphonic acid; 33870-EP2275420A1; 33870-EP2295055A2; 33870-EP2295416A2; 33870-EP2295426A1; 33870-EP2295427A1; 33870-EP2298748A2; 33870-EP2298764A1; 33870-EP2298765A1; 33870-EP2305642A2; 33870-EP2311453A1; 33870-EP2311808A1; 33870-EP2311829A1; AB00053311-04; AB00053311-05; AB00053311_06; A814662; Q251698; {S-[2-(3-Aminopropylamino)ethyl]} phosphorothioate; 2-(3-azanylpropylamino)ethylsulfanylphosphonic acid; J-013390; J-519582; SR-01000075680-1; SR-01000075680-3; SR-01000075680-5; 2-(3-Aminopropyl)aminoethyl phosphorothioate; WR2721; BRD-K73947551-001-01-0; 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate; 2-(3-aminopropylamino)ethylsulfanylphosphonic acid,trihydrate; Phosphorothioic acid, S-[2-[(3-aminopropyl)amino]ethyl]ester; S-2-(3-aminopropylamino)ethyl O,O-dihydrogen phosphorothioate; {S-[2-[(3-Aminopropyl)amino]ethyl]} dihydrogen phosphorothioate; Ethanethiol, {S-[(3-aminopropyl)amino]-,} dihydrogen phosphate- (ester)
    Click to Show/Hide
Molecular Type
Small molecule
Disease Mucositis [ICD-11: CA00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C5H15N2O3PS
PubChem CID
2141
Canonical SMILES
C(CN)CNCCSP(=O)(O)O
InChI
1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
InChIKey
JKOQGQFVAUAYPM-UHFFFAOYSA-N
CAS Number
CAS 20537-88-6
ChEBI ID
CHEBI:2636
TTD Drug ID
D06CIE
DrugBank ID
DB01143
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Paclitaxel      Taxus brevifolia     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Induction Cell cycle arrest in G2/M phase
                    In-vitro Model Hec50co Endometrial cancer Homo sapiens
                    In-vivo Model Amifostine effect on in vivo tumor growth was tested in athymic mice.
                    Experimental
                    Result(s)		 Amifostine and paclitaxel shown a potential anticancer synergistic effect in vitro and in vivo, whereas amifostine maintained a protective role in peripheral blood profiles.
Target and Pathway
Target(s) Toxic reactive metabolite (TRM)  Molecule Info  [1]
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Reference 2 A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res. 2005 Oct 15;65(20):9517-24.
 Download Picture         KEGG Link